This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.48% per year. These returns cover a period from January 1, 1988 through May 5, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
medical: Archive
The Zacks Analyst Blog Highlights Microsoft, AstraZeneca and BlackRock, Taylor Devices and Geospace Technologies
by Zacks Equity Research
MSFT, AZN, and BLK lead Zacks' top stock picks, while TAYD and GEOS show resilience despite microcap market pressures.
AZNPositive Net Change MSFTPositive Net Change BLKNegative Net Change GEOSNegative Net Change TAYDPositive Net Change
computers finance industrial-products medical
Zacks.com featured highlights include Flex, CVS Health, Urban Outfitters and Exelixis
by Zacks Equity Research
FLEX, CVS, URBN and EXEL stand out as GARP picks with strong growth outlooks and discounted PEG ratios.
CVSPositive Net Change URBNNegative Net Change EXELPositive Net Change FLEXNegative Net Change
computers medical retail
Top Stock Reports for Microsoft, AstraZeneca & BlackRock
by Mark Vickery
MSFT, AZN, and BLK earn praise in fresh Zacks reports, with AI, pharma pipelines, and AUM growth fueling long-term outlooks.
AZNPositive Net Change MSFTPositive Net Change BLKNegative Net Change GEOSNegative Net Change TAYDPositive Net Change
computers finance industrial-products medical
4 Attractive GARP Picks for Your Portfolio Based on PEG Ratio
by Urmimala Biswas
Here are four discounted PEG stocks that qualify our screening criteria and could be good picks. These are FLEX, CVS, URBN and EXEL.
CVSPositive Net Change URBNNegative Net Change EXELPositive Net Change FLEXNegative Net Change
computers medical retail smart-health tech-stocks
Is the Options Market Predicting a Spike in Inspire Medical Systems Stock?
by Zacks Equity Research
Investors need to pay close attention to INSP stock based on the movements in the options market lately.
INSPNegative Net Change
medical
HIMS' Subscriptions Power Personalized Care & Recurring Revenue Growth
by Debanjana Dey
Hims & Hers' 38.4% subscriber growth and $576.4 million online revenues highlight the power of its personalized subscription model.
HIMSNegative Net Change LFMDPositive Net Change DOCSNegative Net Change
medical medical-devices
BMY Reports Positive Data on Sotyktu From Arthritis Study
by Zacks Equity Research
Bristol Myers' Sotyktu hits key goals in late-stage PsA trial, fueling hopes for expansion amid recent pipeline setbacks.
NVSPositive Net Change BMYPositive Net Change BAYRYPositive Net Change BNTXNegative Net Change
biotechnology biotechs medical pharmaceuticals
Is the Options Market Predicting a Spike in Kura Oncology Stock?
by Zacks Equity Research
Investors need to pay close attention to KURA stock based on the movements in the options market lately.
KURANegative Net Change
medical
Is the Options Market Predicting a Spike in Dentsply Sirona Stock?
by Zacks Equity Research
Investors need to pay close attention to XRAY stock based on the movements in the options market lately.
XRAYNegative Net Change
medical
Novavax's COVID-Flu Combo Shot Shows Strong Immune Response
by Zacks Equity Research
NVAX's COVID-flu combo shot sparks strong immunity in seniors, fueling plans for further late-stage trials.
SNYPositive Net Change PFEPositive Net Change MRNANegative Net Change NVAXPositive Net Change
biotechs medical messenger-rna pharmaceuticals vaccines
CVS Health's MBR Improves: Can It Sustain Amid Elevated Cost Trends?
by Moumi Mondal
CVS posts its first favorable MBR in quarters, but elevated cost trends test its ability to sustain the gains.
UNHPositive Net Change CVSPositive Net Change ELVPositive Net Change
medical medical-devices
UnitedHealth's Medical Membership Rises: Can It Maintain the Momentum?
by Zacks Equity Research
UNH's medical membership tops 50M amid rising demand. However, high Medicare costs cloud its growth outlook.
UNHPositive Net Change HUMPositive Net Change ELVPositive Net Change
finance insurance medical
Insmed Stock Jumps 29% on Encouraging PAH Study Results
by Zacks Equity Research
INSM eyes the next steps as TPIP hits all endpoints in the PAH study, setting the stage for late-stage trials and broader potential in lung disease.
UTHRPositive Net Change INSMNegative Net Change LQDAPositive Net Change
biotechs medical
CRISPR Therapeutics Gains 14% in a Month: How to Play the Stock?
by Sundeep Ganoria
CRSP surges 14% on encouraging CTX310 data and growing Casgevy sales, despite early-stage pipeline risks.
VRTXPositive Net Change BEAMNegative Net Change NTLANegative Net Change CRSPNegative Net Change
biotechs cancer crispr gene-editing gene-therapy healthcare medical
DOCS Boosts Client Retention via Workflow Integration and AI Tools
by Debanjana Dey
Doximity strengthens client loyalty by embedding AI tools and clinical workflows into its platform for medical professionals.
VEEVNegative Net Change GDRXNegative Net Change DOCSNegative Net Change
medical medical-devices
Reasons to Add DENTSPLY SIRONA Stock to Your Portfolio Now
by Zacks Equity Research
XRAY continues to gain traction from a robust product portfolio. However, the macroeconomic factors, such as weakened global demand, persist.
ANGONegative Net Change XRAYNegative Net Change CVSPositive Net Change ITGRNegative Net Change
medical medical-devices
ISRG Margin Outlook Dips on Tariffs, Demand Signals Stay Strong
by Harshit Gupta
Intuitive Surgical trims margin outlook on tariff headwinds, but strong procedure growth and financial resilience bolster its long-term case.
MDTPositive Net Change ISRGNegative Net Change ZBHNegative Net Change
medical medical-devices
NVO Stock Gains After Parvus Asset Management Builds Stake
by Zacks Equity Research
Novo Nordisk jumps 5% as Parvus Asset Management builds a stake to sway CEO succession amid leadership shakeup and pipeline buzz.
NVSPositive Net Change NVOPositive Net Change LLYPositive Net Change BAYRYPositive Net Change
biotechnology medical pharmaceuticals
BrightSpring's Home Health Arm Soars: What's Powering Growth?
by Sridatri Sarkar
BTSG's Home Health Care Q1 2025 sales surge 21%, fueled by Medicare Advantage gains and high patient satisfaction.
CAHPositive Net Change ADUSPositive Net Change BTSGNegative Net Change
medical
Here's Why You Should Retain PODD Stock in Your Portfolio Now
by Zacks Equity Research
Insulet's Omnipod 5 gains traction with global expansion and rising Type 2 adoption despite economic and competitive hurdles.
PBHPositive Net Change PODDPositive Net Change PAHCPositive Net Change INSPNegative Net Change
medical
FDA Places Clinical Hold on Gilead's HIV Studies, Stock Down
by Zacks Equity Research
GILD slides 2.6% after FDA halts trials for HIV candidates, GS-1720 and GS-4182, over safety concerns in patients.
GSKPositive Net Change NVSPositive Net Change GILDPositive Net Change BAYRYPositive Net Change
biotechnology biotechs medical pharmaceuticals
Should You Continue to Hold Prestige Consumer Stock in Your Portfolio?
by Zacks Equity Research
PBH rides strong on e-commerce gains and brand innovations, but debt load and forex risks cast a shadow on future growth.
CORPositive Net Change PBHPositive Net Change PAHCPositive Net Change HIMSNegative Net Change
medical medical-devices
Can Hologic Lean on Its Strengths in a Tough Macroeconomic Climate?
by Moumi Mondal
HOLX grapples with global headwinds, but growth in Diagnostics and Breast Health service lifts confidence.
MDTPositive Net Change HOLXPositive Net Change QGENPositive Net Change
medical medical-devices
BrightSpring Soars to All-Time High on Quality Strength: Still a Buy?
by Urmimala Biswas
BTSG stock hits an all-time high with a 120% gain as soaring quality ratings and strong Q1 results fuel investor confidence.
AMEDPositive Net Change OPCHPositive Net Change BTSGNegative Net Change
earnings-outlook earnings-report healthcare medical medical-devices
Merck Secures FDA Nod for New RSV Antibody Enflonsia in Infants
by Zacks Equity Research
MRK wins early FDA approval for RSV antibody Enflonsia in infants, with U.S. launch planned before the 2025-26 season.
SNYPositive Net Change AZNPositive Net Change PFEPositive Net Change MRKPositive Net Change
biotechs medical pharmaceuticals vaccines